Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Curi RMB Capital LLC

Curi RMB Capital LLC cut its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 23.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,838 shares of the medical research company's stock after selling 5,457 shares during the quarter. Curi RMB Capital LLC's holdings in Edwards Lifesciences were worth $1,321,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP lifted its position in Edwards Lifesciences by 27.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,995,208 shares of the medical research company's stock worth $221,743,000 after purchasing an additional 653,577 shares during the period. First Trust Advisors LP increased its stake in Edwards Lifesciences by 66.5% in the fourth quarter. First Trust Advisors LP now owns 270,611 shares of the medical research company's stock valued at $20,033,000 after acquiring an additional 108,057 shares during the period. Forum Financial Management LP boosted its holdings in Edwards Lifesciences by 88.2% during the fourth quarter. Forum Financial Management LP now owns 5,780 shares of the medical research company's stock valued at $428,000 after purchasing an additional 2,709 shares in the last quarter. GeoWealth Management LLC grew its stake in shares of Edwards Lifesciences by 65.5% in the 4th quarter. GeoWealth Management LLC now owns 1,897 shares of the medical research company's stock valued at $140,000 after purchasing an additional 751 shares during the period. Finally, Canada Pension Plan Investment Board raised its holdings in shares of Edwards Lifesciences by 80.1% in the 4th quarter. Canada Pension Plan Investment Board now owns 762,740 shares of the medical research company's stock worth $56,466,000 after buying an additional 339,299 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 11,250 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the sale, the chief financial officer now owns 30,387 shares in the company, valued at $2,153,526.69. This represents a 27.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the transaction, the vice president now owns 47,206 shares of the company's stock, valued at approximately $3,295,450.86. This represents a 16.75 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,853 shares of company stock worth $5,163,062. Corporate insiders own 0.34% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on EW. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Barclays boosted their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday. Canaccord Genuity Group boosted their price target on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research note on Friday. Finally, Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $79.45.

Edwards Lifesciences Trading Up 1.2 %

EW stock traded up $0.93 during midday trading on Friday, hitting $76.06. 6,328,689 shares of the company's stock were exchanged, compared to its average volume of 4,987,535. The stock has a market capitalization of $44.71 billion, a PE ratio of 10.91, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The business has a 50-day simple moving average of $70.93 and a two-hundred day simple moving average of $71.02.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. During the same quarter in the prior year, the company earned $0.66 earnings per share. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.